Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology

Sector: Healthcare

Phone: 403-670-7377

Fax: 403-283-0858

Website: oncolyticsbiotech.com

Address:

322 11th Avenue SW, Suite 804, Calgary, Canada

Arrankar2099 Jun. 23 at 4:55 PM

$ONCY

0 · Reply

FoxM07 Jun. 23 at 3:53 PM

$ONCY doldrums of summer are upon us. All the big wigs are in the Hamptons, so Jared has his work cut out for him. Not to worry, even if the SP drifts back to $0.50, our new ceo is so richly compensated that all he has to do is sell Oncy at a 100% premium and he'll still pocket $7,000,000+.

0 · Reply

Arrankar2099 Jun. 23 at 2:14 PM

$ONCY Party's over?

0 · Reply

gopatzgo Jun. 21 at 5:46 PM

$ONCY not to get political but maybe or perhaps a boost to the biotech sector is long overdue

1 · Reply

Newbilly Jun. 20 at 8:07 PM

$ONCY added a few last 10 mins

0 · Reply

archetypal Jun. 20 at 5:42 PM

$ONCY Red bouncing ball today

0 · Reply

DorianMD Jun. 20 at 2:39 PM

$ONCY buy the dip before it hits 1 dollar

0 · Reply

smartmoney43 Jun. 20 at 12:35 PM

$ONCY do we have 0.90 today?

2 · Reply

davidknowles Jun. 19 at 9:00 PM

$ONCY Is it possible the new CEO was hired simply because his resume would cause an increase in share price? Mission accomplished. Now, from the old ONCY playbook, could they do an offering at the current price, followed by a reverse split? We’ll see, but it is as likely as any other scenario.

0 · Reply

sumerian Jun. 19 at 6:58 PM

$ONCY In at $0.48, out at $0.72, booked 50% profit. “Your job is to make money, not pick exact tops and bottoms.” Plan is to double down and let it ride for 2-3 years although I don’t foresee more than $2.50 longer term

1 · Reply

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 4 weeks ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 7:21 PM EDT - 5 weeks ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 5 weeks ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 6 weeks ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 2 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 2 months ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 11:11 AM EST - 3 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 7:00 AM EST - 3 months ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 4 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 4 months ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 4 months ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 4 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Feb 7, 2025, 9:24 PM EST - 4 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Jan 22, 2025, 7:00 AM EST - 5 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Jan 15, 2025, 7:02 AM EST - 5 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Dec 23, 2024, 7:00 AM EST - 6 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Dec 18, 2024, 7:00 AM EST - 6 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Dec 3, 2024, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Nov 13, 2024, 9:01 PM EST - 7 months ago

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 7 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 11, 2024, 7:00 AM EST - 8 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oct 4, 2024, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Sep 19, 2024, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Sep 6, 2024, 8:00 AM EDT - 10 months ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Aug 2, 2024, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Aug 1, 2024, 7:55 PM EDT - 11 months ago

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:01 PM EDT - 11 months ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 24, 2024, 7:00 AM EDT - 11 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Jun 20, 2024, 7:26 AM EDT - 1 year ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

May 24, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 16, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

May 15, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 9, 2024, 8:48 PM EDT - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

May 8, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Mar 9, 2024, 1:09 AM EST - 1 year ago

Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL IMRX

Mar 5, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Feb 28, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Feb 15, 2024, 8:00 AM EST - 1 year ago

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Feb 14, 2024, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Arrankar2099 Jun. 23 at 4:55 PM

$ONCY

0 · Reply

FoxM07 Jun. 23 at 3:53 PM

0 · Reply

Arrankar2099 Jun. 23 at 2:14 PM

$ONCY Party's over?

0 · Reply

gopatzgo Jun. 21 at 5:46 PM

$ONCY not to get political but maybe or perhaps a boost to the biotech sector is long overdue

1 · Reply

Newbilly Jun. 20 at 8:07 PM

$ONCY added a few last 10 mins

0 · Reply

archetypal Jun. 20 at 5:42 PM

$ONCY Red bouncing ball today

0 · Reply

DorianMD Jun. 20 at 2:39 PM

$ONCY buy the dip before it hits 1 dollar

0 · Reply

smartmoney43 Jun. 20 at 12:35 PM

$ONCY do we have 0.90 today?

2 · Reply

davidknowles Jun. 19 at 9:00 PM

0 · Reply

sumerian Jun. 19 at 6:58 PM

1 · Reply

De_man Jun. 19 at 5:07 PM

$ONCY All the talk about billions, oh well at least it adds excitement although unrealistic to expect anything more than maybe 2.5 billion tops IMO. Even Noteable has gone from 28 billion starting point to the 10-15 billion sweet spot for BP. Onc does not have any yet approved fda product so everything is still in question and they need to get an fda approved trial going or AA to really get the interest up. As to pfizer, they are not interested as they sold their ci avalumab shortly after it failed in the onc bracelet trial. How the heck did pfizer talk onc into changing from atizalizumab to avalumab is astound especially after the success of aware1. Some backyard talk about taking them out if successful my guess. As for Matt's medical leave, we will never know and maybe just a way of phasing him out but hard to say what really happened. As for the new CEO, this would suggest that a BO is not on the table as of yet or they would not need him but going forward does help for sure IMO.

1 · Reply

cbachand Jun. 19 at 3:21 PM

Jared Kelly is an accomplished lawyer and executive with a distinguished career in corporate law, particularly within the biotechnology sector. Mr. Kelly recently served as head of legal and corporate strategy at Ambrx and played a central role in its $2 billion sale to Johnson & Johnson.$ONCY

1 · Reply

cbachand Jun. 19 at 3:19 PM

$ONCY Oncolytics Biotech (NASDAQ: ONCY) has appointed Jared Kelly as its new CEO and Board member. Kelly, who recently helped orchestrate Ambrx Biopharma's $2B sale to Johnson & Johnson, brings expertise in transformative deals and corporate strategy. The company's lead drug pelareorep, an immunotherapeutic agent with FDA Fast Track designation, has shown promising results in multiple cancers. In metastatic pancreatic cancer trials, it achieved >60% objective response rate, with 2-year survival rates 4-6 times higher than controls. The drug has also demonstrated efficacy in metastatic breast cancer and anal canal cancer trials. Kelly received significant equity incentives, including 2.85M stock options at CAD$0.57 vesting over three years, 1.9M performance-based options, and restricted stock units tied to potential acquisition or licensing deals.

1 · Reply

FoxM07 Jun. 19 at 1:55 PM

$ONCY stop talking about an acquisition by BP in the billions. CEO Jared Kelly could end up receiving in & around $70 million in compensation per billion received. This is the stuff of fantasy. If there was a realistic chance that the CEO could receive such compensation, every BP CEO would have quit their current jobs to apply for Oncy.

4 · Reply

smartmoney43 Jun. 19 at 1:00 PM

$ONCY its getting really interesting now!

1 · Reply

Peter1735 Jun. 19 at 1:00 PM

$ONCY creeping up, just last week it was at $0.32

0 · Reply

DorianMD Jun. 18 at 9:30 PM

$ONCY strong 💪 and steady

0 · Reply

CaseyLe Jun. 18 at 5:45 PM

$ONCY 🚨 1 Million In Volume 🚨

0 · Reply

Canadafan14 Jun. 18 at 5:35 PM

$ONCY Not only will there not be a R/S, they will not need one. Using the existing trends & the New CEO who has very large bonus to sell the company: There will be nice & well awaited movement upwards. The $1PS on the Nas, at present trends well above the Required $1PS by next week at latest. Could be some in-term-profit taking , by those who do not understand the true upside [potential. The New CEO sold a biotech to Johnson & Johnson for $2 billion, only after being that the company for a few months. his employment announcement has made things very clear, he was hired to get a business deal. BTW for this lacking in math , every $BILLLION/ps = about $10PS for ONCY The nickels & dimes people are getting exited about...peanuts.

1 · Reply

davidknowles Jun. 18 at 4:32 PM

$ONCY my read: new CEO has the credibility to raise the price enough for a offering followed by a RS. Nothing is changing with the partnerships and/or buyouts. Our little virus is just not strong enough. Full stop. Wish I had bought at .35 to make a nice scoop.

1 · Reply

Winning_calls Jun. 18 at 4:30 PM

$ONCY 👊👊👊

0 · Reply

DorianMD Jun. 18 at 3:42 PM

$ONCY 1 dolla!!

0 · Reply

Market Cap	65.07M
Revenue (ttm)	0.00
Net Income (ttm)	-23.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	447,675
Avg Vol	804,316
Day's Range	N/A - N/A
Shares Out	94.28M
Stochastic %K	80%
Beta	0.71
Analysts	Strong Sell
Price Target	$3.53